Home > Boards > Canadian > Cannabis > Canopy Growth Corp (WEED)

Canopy Growth Reports Full Year and 4th Quarter

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
JohnCM Member Profile
 
Followed By 654
Posts 60,038
Boards Moderated 33
Alias Born 06/01/08
160x600 placeholder
Martha Stewart CBD Unveils New Fall Flavors and Limited-Edition Holiday Products, Expanding Portfolio of Best-In-Class CBD Wellness Offerings PR Newswire (US) - 10/28/2021 7:00:00 AM
Canopy Growth to Report Q2 2022 Financial Results on November 5, 2021 PR Newswire (US) - 10/22/2021 7:00:00 AM
Canopy Growth to Report Q2 2022 Financial Results on November 5, 2021 PR Newswire (Canada) - 10/22/2021 7:00:00 AM
Canopy Growth Announces Plan to Acquire Wana Brands, the #1 Cannabis Edibles Brand in North America PR Newswire (Canada) - 10/14/2021 7:00:00 AM
Canopy Growth Announces Plan to Acquire Wana Brands, the #1 Cannabis Edibles Brand in North America PR Newswire (US) - 10/14/2021 7:00:00 AM
Karma Beverages Launches CBD Water - Next Evolution of Premium Infused Waters Portfolio PR Newswire (US) - 10/4/2021 8:30:00 AM
Canopy Growth Announces Results of Annual General and Special Shareholder Meeting PR Newswire (Canada) - 9/15/2021 10:00:00 AM
Canopy Growth Announces Results of Annual General and Special Shareholder Meeting PR Newswire (US) - 9/15/2021 10:00:00 AM
Introducing whisl, an Innovative CBD Vape Designed to Manage Your Mood Throughout the Day PR Newswire (US) - 9/14/2021 7:30:00 AM
STORZ & BICKEL Unveils New Limited Edition VOLCANO ONYX, Enhanced CRAFTY+ and First-Ever MIGHTY+ PR Newswire (US) - 9/9/2021 12:00:00 PM
STORZ & BICKEL Unveils New Limited Edition VOLCANO ONYX, Enhanced CRAFTY+ and First-Ever MIGHTY+ PR Newswire (Canada) - 9/9/2021 12:00:00 PM
Canopy Growth To Participate In Barclays Global Consumer Staples Virtual Conference On September 8, 2021 PR Newswire (US) - 8/26/2021 7:00:00 AM
Canopy Growth To Participate In Barclays Global Consumer Staples Virtual Conference On September 8, 2021 PR Newswire (Canada) - 8/26/2021 7:00:00 AM
Canopy Growth to Hold Virtual Annual General & Special Meeting of Shareholders PR Newswire (Canada) - 8/16/2021 7:00:00 AM
Canopy Growth to Hold Virtual Annual General & Special Meeting of Shareholders PR Newswire (US) - 8/16/2021 7:00:00 AM
Canopy Growth Reports First Quarter Fiscal 2022 Financial Results PR Newswire (US) - 8/6/2021 7:00:00 AM
Canopy Growth Reports First Quarter Fiscal 2022 Financial Results PR Newswire (Canada) - 8/6/2021 7:00:00 AM
Share Your Pack, Not Your Pre-Roll: Canopy Growth Unveils New PRJ Line-Up PR Newswire (US) - 7/27/2021 8:00:00 AM
Partagez votre paquet, pas vos joints préroulés : Canopy Growth dévoile une nouvelle gamme de joints préroulés PR Newswire (Canada) - 7/27/2021 8:00:00 AM
Share Your Pack, Not Your Pre-Roll: Canopy Growth Unveils New PRJ Line-Up PR Newswire (Canada) - 7/27/2021 8:00:00 AM
Canopy Growth to Report First Quarter Fiscal Year 2022 Financial Results on August 6, 2021 PR Newswire (Canada) - 7/23/2021 7:00:00 AM
Canopy Growth to Report First Quarter Fiscal Year 2022 Financial Results on August 6, 2021 PR Newswire (US) - 7/23/2021 7:00:00 AM
Canopy Growth Completes Acquisition of Supreme PR Newswire (US) - 6/23/2021 7:01:00 AM
Canopy Growth Completes Acquisition of Supreme PR Newswire (Canada) - 6/23/2021 7:01:00 AM
Little Green Pharma To Accelerate Growth Strategy With Acquisition of World-Class Production and Manufacturing Facility in De... PR Newswire (Canada) - 6/22/2021 6:00:00 AM
JohnCM   Friday, 05/29/20 07:23:46 AM
Re: None
Post # of 125223 
Quote:
Canopy Growth Reports Full Year and 4th Quarter Fiscal 2020 Financial Results; Provides Strategic Review Update

May 29, 2020 • 7:02 AM EDT
Technical420.com
BY ANTHONY VARRELL

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NYSE: CGC) today announced its financial results for the fourth quarter and full twelve-month fiscal year ended March 31, 2020. The Company is also sharing details of its new strategic plan aimed at winning in priority markets and categories and executing a path to profitability. All financial information in this press release is reported in millions of Canadian dollars, unless otherwise indicated. The fourth quarter and full twelve-month fiscal year 2020 financial results presented in this press release have been prepared in accordance with U.S. GAAP.

“Through the COVID-19 pandemic we have worked hard to ensure the health and well-being of our teams and customers and the continuity of our business. During this time, our team has rolled out our exciting new cannabis-infused beverages and vape products in Canada and a portfolio of CBD products in the US,” shared CEO David Klein. “True to key priorities that I have outlined for Canopy, we have taken steps to align our capacity with the current market demand and focus our resources against the core markets with the largest and most tangible near-term profit opportunity.”

Added Klein, “I am excited to implement our strategy reset and organization redesign over the course of fiscal 2021. We have a renewed strategic focus and a clear change agenda that is already underway. We are building what we believe is the best cannabis company in the world by putting the consumer at the heart of everything we do and are re-aligning our organization to be faster and more agile.”

Strategic and Organizational Update

Canopy Growth’s overall strategy is to unleash the full potential of cannabis, capture sizable market share in focus categories and markets and execute a path to profitability to build sustainable, long-term shareholder value.

The Company no longer strives to be the first to every market, but strives to the best and become a leading consumer insights and product development company in select priority markets, that matches products and consumer preferences in the cannabis space. To achieve this, Canopy Growth will focus on:

Becoming a relentlessly consumer-centric organization by building world-class consumer insights and analytics, coupled with focused, leading-edge R&D and innovation to produce a differentiated product portfolio that will delight consumers. The Company will bring these products to the hands of consumers through best-in-class sales execution;

Markets and product categories with the highest and most tangible profit opportunities in the near term. Core markets will be Canada, US and Germany with focus on recreational and medical. To capture future opportunities in emerging markets and categories outside the core, Canopy Growth will deploy an asset-light approach;

Driving quality in all aspects of our operation and be positioned to deliver the right product at the right time at the right price from the right facility; and

Continuing to lead the industry and set industry standards. This includes spearheading the next phase of the cannabis industry evolution and shaping how the industry evolves. The Company will continue to give back to neighbors and communities through its Grow Good Together initiatives.

Canopy Growth expects Fiscal 2021 to be a transition year as the Company resets its strategic focus, rolls out a new organizational design, and implements a comprehensive operational and supply chain productivity program. Given this, as well as the significant COVID-19 related uncertainties that exist, the Company is withdrawing its previously communicated milestones for achieving positive Adjusted EBITDA and Net Income. Depending on the impacts of COVID-19, Canopy Growth may provide new metrics by which to measure the Company’s performance in the second half of fiscal 2021.

Generated Net Revenue of $399 million in FY 2020, up 76% over FY 2019

In connection with previously announced organizational and strategic review, recorded impairment and restructuring charges of $743 million; the majority of which are non-cash charges

Gross Margin of (85)% in Q4 FY2020; excluding restructuring and other charges, achieved Adjusted Gross Margin of 42%

Net Loss of $1.3 billion; Adjusted EBITDA loss of $102 million in Q4 2020

Fourth Quarter Fiscal 2020 Financial Summary

Net revenue Gross margin percentage Adjusted gross margin percentage Net loss Adjusted EBITDA2 Free cash flow

Reported $107.9 (85%) 42% $(1,326.4) $(102.0) $(304.7)
vs. Q3 2020 (13%) NM 1,100 bps (1110%) (5%) 15%
vs. Q4 2019 15% NM 2,000 bps (282%) (8%) 22%

1 Adjusted gross margin is a non-GAAP measure, and for Q4 2020 excludes (i) restructuring and other charges of $132.1 million related to the impact of restructuring actions; and (ii) $4.7 million related to the flow-through of inventory step-up associated with fiscal 2020 business combinations. See “Non-GAAP Measures”.

2 Adjusted EBITDA is a non-GAAP measure. See “Non-GAAP Measures”.

3 Free cash flow is a non-GAAP measure. See “Non-GAAP Measures”.

4 Adjusted gross margin is a non-GAAP measure, and for fiscal 2020 excludes charges of $136.8 million incurred in Q4 2020, as described in footnote 1 above. See “Non-GAAP Measures”.

Fourth Quarter Fiscal 2020 Corporate Financial Highlights

Revenues: Net revenue in Q4 2020 decreased 13% versus Q3 2020 driven primarily by lower Canadian recreational revenue.

Gross margin: : Reported gross margin, including one-time restructuring and other charges, was (85%). Adjusted gross margin, excluding one-time restructuring and other charges and inventory step-up costs, was 42% in Q4 2020, representing an increase of 1,100 bps from Q3 2020. Adjusted gross margin performance in Q4 2020 was positively impacted by higher facility utilization and growth in high margin international medical cannabis sales.

Operating expenses: SG&A expenses in Q4 2020 increased 17% over Q3 2020 driven primarily by a combined $15 million increase in General & Administrative and Sales & Marketing expenses.

Net Loss: Net loss of $1.3 billion in Q4 2020, primarily driven by impairment and restructuring charges, other impairment charges which were primarily identified during our annual impairment testing, and other non-cash fair value changes.

Adjusted EBITDA: Adjusted EBITDA loss of $102 million in Q4 2020, a $5 million wider loss versus Q3 2020 driven by lower sales and higher operating expenses.

Cash Position: Gross cash balance was $2.0 billion at March 31, 2020, down from $2.3 billion at the end of Q3 2020 reflecting the EBITDA loss, capital investments and mergers and acquisitions activities.

Restructuring and Impairment Costs: In line with our previous announcement (March 4, 2020), we recorded a pre-tax restructuring and impairment charge of $743 million in Q4 2020, of which $28 million is estimated to be a cash charge. Additionally, we recorded impairment charges of $100 million Q4 2020, which were primarily identified during our annual impairment testing process.

Business & Operational Highlights

COVID-19 response: Management has been closely monitoring the impact of COVID-19, with a focus on the health and safety of our employees, business continuity and supporting our communities. The majority of non-production related staff continue to work from home; we implemented daily screening process for production facility access; temporarily closed corporate-owned retail stores in mid-March but re-opened 20 stores with reduced hours as well as click & collect ordering; rolled out click & collect to 100% of all Tokyo Smoke and Tweed licensed stores and added same day delivery for Tokyo Smoke partner stores.

UL certified Juju Power 510 battery as well as 510 vape cartridges under Tweed and Twd. brands, representing a total of five SKUs, are available in the Canadian recreational market.

UL certified Tokyo Smoke Luma pod-based vape devices, Luma “Go” pods and Luma “Pause” pods are available in the Canadian recreational market.
Ready to Drink (“RTD”) beverages under Tweed and Houseplant brands, representing a total of three SKUs, are available in the Canadian recreational market.

Company has expanded offering of Hemp-derived CBD products with the launch of a line of First & Free topical creams in select states in the US and the launch of This Works’ line of clinically-proven CBD Booster skin products in the United Kingdom, Germanyand select states in the US.
On May 1, 2020, an indirect wholly-owned subsidiary of Constellation Brands (NYSE:STZ) exercised warrants for approximately C$245 million , representing approximately 5.1% of our issued and outstanding common shares.

Fourth Quarter and Fiscal Year 2020 Financial and Operational Review

(in millions of Canadian dollars, unaudited)

Q4 2020

vs. Q3 2020

vs. Q4 2019

FY2020

vs. FY2019

Canadian recreational revenue

– Business to business

$36.7

(31%)

(36%)

$157.3

34%

– Business to consumer

$13.1

(14%)

12%

$52.0

125%

Canadian recreational revenue

$49.8

(28%)

(28%)

$209.3

49%

Canadian medical revenue

$14.9

1%

29%

$56.8

(17%)

International medical revenue

$20.7

11%

1051%

$68.0

574%

All other revenue

$29.7

(11%)

23%

$105.5

210%

Excise taxes

$(7.2)

(39%)

(42%)

$(40.8)

51%

Net revenue

$107.9

(13%)

15%

$398.8

76%

(in millions of Canadian dollars, unaudited)

Q4 2020

vs. Q3 2020

vs. Q4 2019

FY2020

vs. FY2019

Canadian recreational revenue

– Dry bud1

$48.9

(29%)

51%

$238.1

188%

– Oils, softgels and Cannabis 2.0 products2

$6.3

34%

(83%)

$22.7

-61%

– Other revenue adjustments3

$(5.4)

2%

NM

$(51.5)

NM

Global medical revenue

– Dry bud

$9.8

7%

34%

$35.8

-30%

– Oils and softgels

$25.8

6%

329%

$89.0

224%

All other revenue

$29.7

(11%)

23%

$105.5

210%

Excise taxes4

$(7.2)

(39%)

(42%)

$(40.8)

51%

Net revenue

$107.9

(13%)

15%

$398.8

76%

1 Excludes the impact of other revenue adjustments.

2 Cannabis 2.0 products include cannabis-infused chocolates, cannabis-infused beverages, and cannabis vape products (including power sources such as rechargeable and compact batteries, ready-to-go vape pens, and cartridges/vape pods)

3 Other revenue adjustments represent the Company’s determination of returns and pricing adjustments, and relate to the Canadian recreational business-to-business channel.

4 Excise taxes is presented net of the impact from other revenue adjustments.

Canadian Cannabis

Recreational B2B sales in Q4 2020 decreased 31% from Q3 2020 as growth in softgels, oil, and Cannabis 2.0 products was more than offset by an overall decline in flower and pre-roll joints.

Recreational B2C sales in Q4 2020 decreased 14% from prior quarter due to the expected off peak seasonal demand decline and the closure of corporate-owned retail stores late in the quarter in response to COVID-19.

Medical sales in Q4 2020 remained consistent quarter over quarter (Q3 2020 vs. Q4 2020).

International Cannabis

C3 revenue in Q4 2020 increased 10% over Q3 2020.

Germany cannabis sales increased 14% in Q4 2020 over Q3 2020 benefiting from improved supply and increased demand.

International cannabis revenue accounted for 24% of total cannabis revenues in Q4 2020.

Strategic Acquisitions

This Works sales in Q4 2020 were consistent with seasonally strong Q3 2020.

Storz & Bickel (“S&B”) vaporizer revenue decreased over Q3 2020 due to seasonal decline.

BioSteel Sports Nutrition revenue decreased by 20% over Q3 2020 due to expected seasonal decline and reduction of thirty-party distribution and retail in response to COVID-19.

Webcast and Conference Call Information

The Company will host a conference call and audio webcast with David Klein, CEO and Mike Lee, CFO at 10:00 AM Eastern Time on May 29, 2020.

Webcast Information

A live audio webcast will be available at:
https://produceredition.webcasts.com/starthere.jsp?ei=1308617&tp_key=850fd370f4

Replay Information

A replay of the call will be accessible by webcast, until 11:59 PM ET on August 27, 2020, at
https://produceredition.webcasts.com/starthere.jsp?ei=1308617&tp_key=850fd370f4



Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences